Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2021	Dec. 31, 2020
Revenues	[1]	$ 98,267	$ 107,712
Cost of products sold		73,625	78,553
Gross profit		24,642	29,159
Operating expenses:
Research and development		6,826	5,947
Selling, general and administrative		17,781	17,511
Total operating expenses		24,607	23,458
Operating income		35	5,701
Other expense (income):
Interest and financing expense		242	436
Miscellaneous income		(56)	(165)
Gain on litigation settlement		0	(1,593)
Total other expense (income)		186	(1,322)
(Loss) income before income taxes		(151)	7,023
Income tax provision		79	1,692
Net (loss) income		(230)	5,331
Net income attributable to non-controlling interest		4	99
Net (loss) income attributable to Ultralife Corporation		(234)	5,232
Other comprehensive income:
Foreign currency translation adjustments		129	749
Comprehensive (loss) income attributable to Ultralife Corporation		$ (105)	$ 5,981
Net (loss) income per share attributable to Ultralife Corporation common shareholders – Basic (in dollars per share)		$ (0.01)	$ 0.33
Net (loss) income per share attributable to Ultralife Corporation common shareholders – Diluted (in dollars per share)		$ (0.01)	$ 0.33
Weighted average shares outstanding – Basic (in shares)		16,037	15,902
Weighted average shares outstanding – Diluted (in shares)		16,037	16,096

[1] Sales classified to U.S. include shipments to U.S.-based prime contractors which in some cases may serve non-U.S. projects.